ECSP10010183A - SOLID DISPERSION PRODUCT OF N-ARIL-UREA-BASED DRUGS - Google Patents

SOLID DISPERSION PRODUCT OF N-ARIL-UREA-BASED DRUGS

Info

Publication number
ECSP10010183A
ECSP10010183A EC2010010183A ECSP10010183A ECSP10010183A EC SP10010183 A ECSP10010183 A EC SP10010183A EC 2010010183 A EC2010010183 A EC 2010010183A EC SP10010183 A ECSP10010183 A EC SP10010183A EC SP10010183 A ECSP10010183 A EC SP10010183A
Authority
EC
Ecuador
Prior art keywords
solid dispersion
urea
aril
dispersion product
based drugs
Prior art date
Application number
EC2010010183A
Other languages
Spanish (es)
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of ECSP10010183A publication Critical patent/ECSP10010183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto que comprende al menos un agente con actividad farmacéutica basado en N-aril urea que se obtiene mediante a) la preparación de una mezcla líquida que contiene al menos un agente activo, al menos un agente formador de matriz farmacéuticamente aceptable, al menos un agente tensioactivo farmacéuticamente aceptable y al menos un solvente, y b) la eliminación de los uno o más solventes de la mezcla líquida, para obtener el producto de dispersión sólida.A product comprising at least one agent with pharmaceutical activity based on N-aryl urea which is obtained by a) the preparation of a liquid mixture containing at least one active agent, at least one pharmaceutically acceptable matrix forming agent, at least one pharmaceutically acceptable surfactant and at least one solvent, and b) the removal of the one or more solvents from the liquid mixture, to obtain the solid dispersion product.

EC2010010183A 2007-10-19 2010-05-17 SOLID DISPERSION PRODUCT OF N-ARIL-UREA-BASED DRUGS ECSP10010183A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010183A true ECSP10010183A (en) 2010-06-29

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010183A ECSP10010183A (en) 2007-10-19 2010-05-17 SOLID DISPERSION PRODUCT OF N-ARIL-UREA-BASED DRUGS

Country Status (18)

Country Link
EP (1) EP2197425A2 (en)
JP (1) JP2011500649A (en)
KR (1) KR20100087170A (en)
CN (1) CN101827584A (en)
AU (1) AU2008313622A1 (en)
BR (1) BRPI0818340A2 (en)
CA (1) CA2699301A1 (en)
CO (1) CO6270206A2 (en)
CR (1) CR11442A (en)
DO (1) DOP2010000117A (en)
EC (1) ECSP10010183A (en)
GT (1) GT201000102A (en)
MX (1) MX2010004291A (en)
PA (1) PA8800101A1 (en)
RU (1) RU2010119929A (en)
UA (1) UA100865C2 (en)
WO (1) WO2009050291A2 (en)
ZA (1) ZA201002095B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Protein kinase inhibitors
BR112012031516A2 (en) * 2010-06-09 2016-11-08 Abbott Lab solid dispersions containing kinase inhibitors
CN103917236A (en) 2011-11-11 2014-07-09 诺华股份有限公司 Methods of treating proliferative diseases
DK2782557T3 (en) * 2011-11-23 2018-12-10 Array Biopharma Inc PHARMACEUTICAL FORMULATIONS
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CO6270206A2 (en) 2011-04-20
CN101827584A (en) 2010-09-08
RU2010119929A (en) 2011-11-27
DOP2010000117A (en) 2010-05-15
BRPI0818340A2 (en) 2015-04-22
PA8800101A1 (en) 2009-05-15
JP2011500649A (en) 2011-01-06
WO2009050291A3 (en) 2010-04-08
CR11442A (en) 2010-09-06
CA2699301A1 (en) 2009-04-23
MX2010004291A (en) 2010-08-02
WO2009050291A2 (en) 2009-04-23
GT201000102A (en) 2012-03-12
UA100865C2 (en) 2013-02-11
ZA201002095B (en) 2011-11-30
KR20100087170A (en) 2010-08-03
EP2197425A2 (en) 2010-06-23
AU2008313622A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
ECSP10010184A (en) SOLID DISPERSION PRODUCT CONTAINING A N-ARIL-UREA-BASED COMPOUND
ECSP10010183A (en) SOLID DISPERSION PRODUCT OF N-ARIL-UREA-BASED DRUGS
AR080736A1 (en) PHARMACEUTICAL COMPOSITION OF RAPID DISSOLUTION, USEFULLY DIVERSE, AND PROCESS TO PREPARE IT
AR059350A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
CO6470799A2 (en) ORAL MICROEMULSIFYING ORAL PHARMACEUTICAL COMPOSITION OF A HYDROPHYL PHARMACO AND THIS PREPARATION METHOD
CL2015001961A1 (en) (divisional application 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients
WO2010041141A3 (en) Oil-based foamable carriers and formulations
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
AR059359A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING PLECONARIL
UY32761A (en) THERMOSTABLE PREPARATIONS AND INSULINIC PREPARATIONS STABLE TO VIBRATIONS
AR051969A1 (en) METHODS AND COMPOSITIONS THAT USE IMMUNOMODULATING COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM
CO6251200A2 (en) METHOD FOR MODULATING THE MICROENCAPSULATED ACTIVE INGREDIENT RELEASE RATE USED FOR CULTURE PROTECTION
CR20110599A (en) PHARMACEUTICALLY ACTIVE COMPOSITIONS THAT INCLUDE OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES
CY1110037T1 (en) PACKAGES FOR BENZIMIDAZOLYL PYRIDYL ETHERS
AR059357A1 (en) PHARMACEUTICAL FORMULATIONS
PE20110019A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN INSULIN SENSITIZER AND AN INSULIN SECRETAGOG
CL2007001981A1 (en) COMPOSITION THAT INCLUDES AT LEAST ONE AGROCHEMICAL ACTIVE PRINCIPLE OF THE PIRETROID GROUP, AT LEAST A TENSIOACTIVE, AND AT LEAST A SOLVENT NOT MISSIBLE IN WATER; PROCEDURE FOR THE FIGHT AGAINST ANIMAL PESTS; AND ITS USE.
AR052787A1 (en) PROCESS TO PREPARE FORMULATIONS OF LIPOFILIC ACTIVE SUBSTANCES THROUGH ATOMIZATION LIOPHILIZATION
CL2008000931A1 (en) Cross-linked oral vaccine solids containing a pharmaceutically active ingredient, a bioadhesive, an oligasacaride, a mediator mixture comprising an emulsifier and one or more monosaccharides and / or disacarids; method for its preparation; use of solida oral vaccine particle.
CL2011001207A1 (en) Extrudates containing at least one needle-shaped pharmaceutically active substance, such that the ratio between the particle size of the needle-shaped pharmaceutically active substance and the diameter of the chain is at least 1:20; pharmaceutical composition; and its use to prepare medicines.
AR062626A1 (en) SULFONATE POLYSTYRENE POLYMER TABLETS, ITS PREPARATION AND USE
CO6270249A2 (en) FIBER, FILM OR FOAM THAT INCLUDES A PLASTIFIER AND A GEL LINKED TO LOADED CLAY AND METHODS FOR ITS PRODUCTION
AR105503A1 (en) CONCENTRATE CONTAINING ALPROSTADIL
CO2017011220A2 (en) Process for the manufacture of dry powder mixtures
TH104743A (en) Solid diffusion product containing N-aryl urea compounds.